Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #11 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Glenmark Pharmaceuticals Limited (this stock) | 65,885 | 321.6 | 13.0% | 19.2% | 0.21% | 73 | 0 | 31 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 4,018 | 643 | 483 | ₹ |
| March 31, 2026 | 3,771 | 388 | 301 | ₹ |
| Dec. 31, 2025 | 3,901 | 534 | 403 | ₹ |
| Sept. 30, 2025 | 6,047 | 967 | 610 | ₹ |
| June 30, 2025 | 3,264 | 96 | 47 | ₹ |
| March 31, 2025 | 3,256 | 8 | 4 | ₹ |
| Dec. 31, 2024 | 3,388 | 456 | 348 | ₹ |
| Sept. 30, 2024 | 3,434 | 473 | 354 | ₹ |
| June 30, 2024 | 3,244 | 462 | 340 | ₹ |
| March 31, 2024 | 3,063 | 531 | -1,214 | ₹ |
| Dec. 31, 2023 | 2,507 | -521 | -331 | ₹ |
| Sept. 30, 2023 | 3,207 | -124 | -64 | ₹ |
| June 30, 2023 | 3,402 | 333 | 173 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 16,983 | 1,985 | 1,362 |
| March 31, 2025 | 13,322 | 1,399 | 1,047 |
| March 31, 2024 | 11,813 | 36 | -1,434 |
| March 31, 2023 | 12,990 | 868 | 377 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 3,445 | -1,283 | -2,709 | 1,358 | 2,087 |
| March 31, 2025 | -828 | 2 | 787 | 750 | -1,577 |
| March 31, 2024 | -265 | 4,369 | -3,906 | 898 | -1,164 |
| March 31, 2023 | 625 | -528 | -77 | 608 | 18 |
| March 31, 2022 | 1,109 | -333 | -520 | 790 | 319 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 19,908 | 10,512 | 10,484 | 0 | 0 | 11,300 | 6,376 | 1,175 | 3,890 | 3,431 |
| March 31, 2025 | 16,050 | 8,849 | 8,821 | 1,681 | 513 | 9,295 | 5,967 | 1,676 | 3,319 | 3,029 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
